Recent

% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • crossroads4040 crossroads4040 Oct 18, 2012 5:38 PM Flag

    CEO said looking for partners for VX-135 (=ALS 2200)

    Sorry, but this isn't news. Leiden has suggested on at least two other occasions the willingness to partner on 2200. The fact that he needs to make this statement suggests desperation and that there have been no takers to date. Needless to say, the market is unimpressed.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • "Sorry, but this isn't news. Leiden has suggested on at least two other occasions the willingness to partner on 2200."

      Read carefully. Jeff did NOT contact other companies. THEY CONTACTED HIM. Here is his statement:

      "Vertex, maker of the hepatitis C drug Incivek, has received interest from other companies to collaborate on tests of one of its experimental medicines for the liver disease, Chief Executive Officer Jeffrey Leiden said."

      Better cover your short my friend!

    • My message title is misleading. If you read the Bloomberg article carefully, you'll notice that there are more than one company which want 2200 to be combined with their drugs. The other parties are seeking partnerships.

      My speculation on the base of what Peter Mueller said is that one of them would be Bristrol-Myers. Some like Daclatasvir (BMS-790052) would be good enough to be combined with ALS-2200. ACHN also has NS5A inhibitors including a 2nd gen drug. If any one of them is as good as Daclatasvir, and works well when combined with 2200, they can more than match any drug combo GILD can come up with.

 
VRTX
125.08+0.03(+0.02%)May 22 4:00 PMEDT